Successful Use Of Cyclosporine Research Articles

Successful use of cyclosporine to treat acute generalized exanthematous pustulosis

Successful use of cyclosporine to treat acute generalized exanthematous pustulosis

Successful Use of Cyclosporine for Eosinophilic Cystitis in a 64-Year Old Female

Successful Use of Cyclosporine for Eosinophilic Cystitis in a 64-Year Old Female

Successful use of cyclosporine in the treatment of toxic epidermal necrolysis: A case series

Toxic epidermal necrolysis (TEN) is an acute life-threatening disease associated with a high mortality. Systemic corticosteroids, cyclosporine, and intravenous gamma globulins have been used in the treatment with variable results. We report five cases of TEN treated successfully with cyclosporine monotherapy. All the patients presented with severe disease. All the patients received cyclosporine 3–5 mg/kg/day for an average duration of 5–10 days depending on the clinical response. All the patients recovered without any sequel. No significant side effects were noted in all the five patients except for one patient who developed acute nephrotoxicity. All the five patients were discharged from the hospital by the end of 2 weeks, thus decreasing the hospital stay due to a favorable outcome and early recovery. Cyclosporine in TEN patients is not only a lifesaving drug, but also it is cost-effective. This case series demonstrates the safety and efficacy of the short course of cyclosporine monotherapy in the treatment of TEN.

Successful use of cyclosporine as treatment for eosinophilic cystitis: a case report

Background Eosinophilic cystitis is a rare inflammatory disorder characterized by eosinophilic infiltration of all layers of the urinary bladder wall. Due to lack of consensus and potential for side effect from various therapeutic options, treatment of the disease is often challenging.Case presentation A 64-year old woman with hypertensive nephropathy resulting in stage III chronic kidney disease, obstructive sleep apnea, and obstructive lung disease presented with a 4 month history of dysuria, urgency, frequency, and persistent hematuria. Based on eosinophilic infiltration on bladder wall biopsy in the absence of any evidence of infection, malignancy, or immune disorder, she was diagnosed with eosinophilic cystitis. Despite multiple medication regimens, her symptoms persisted, requiring high-dose prednisone with steroid-related side effects. After four months, she was started on cyclosporine, which led to symptomatic improvement and reduction in prednisone dosage. At that time, repeat urine cytology and cystoscopy did not reveal friable tissues or eosinophiluria.Conclusion This case illustrates the utility of using cyclosporine to treat eosinophilic cystitis in adult patient with multiple comorbid conditions.

Successful use of cyclosporin A in severe Schönlein–Henoch nephritis resistant to both methylprednisolone pulse and azathioprine

Schönlein-Henoch nephritis (SHN) usually presents with micro-haematuria or mild proteinuria but can be associated with heavy proteinuria and nephrotic or acute nephritic syndrome. Although the treatment of SHN is still under debate, it has been suggested that cyclosporin A (CsA) may be beneficial in children with severe SHN, as reported by Ronkainen et al. (Pediatr Nephrol 18:1138-1142, 2003) and Someya et al. (Pediatr Int 46:111-113, 2004). However, histological effects of CsA on severe SHN had not been evaluated in their evaluations. We report the successful use of CsA in a male patient with severe SHN with nephrotic-range proteinuria, who failed to respond to methylprednisolone pulse and azathioprine therapy.

Severe resistant subacute prurigo successfully controlled by long-term cyclosporin

The case of a 50-year-old woman with an intensely pruritic subacute prurigo resistant to multiple therapeutic regimens is described. Therapy with cyclosporin was started, achieving complete control of the disease, demonstrating a good safety profile during long-term treatment. This is the first report on the successful use of cyclosporin for subacute prurigo.

Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome

Hemolytic uremic syndrome (HUS) is a rare, but well-described complication in organ transplant recipients maintained on cyclosporine immunosuppression. Tacrolimus is a newer agent with similar immunosuppressant efficacy. In cases of cyclosporine-related HUS in renal transplant recipients, tacrolimus has been used successfully without recurrence of HUS. 1,2 Tacrolimus has been reported to cause HUS in renal and more recently in cardiac transplant patients. 3,4 We report a case of HUS in a lung transplant recipient receiving tacrolimus who was subsequently converted to cyclosporine without recurrence of HUS.

Cyclosporine-induced migraine with severe vomiting causing loss of renal graft

Successful use of cyclosporine in organ transplant can be associated with unwanted side-effects that can affect graft function. We report three kidney transplant recipients in whom severe migraine headache occurred as a side-effect of cyclosporine therapy. This endangered graft survival in all three and eventually led to loss of graft in two.

Clinical aspects of juvenile rheumatoid arthritis.

This paper reviews studies in epidemiology, differential diagnosis, clinical manifestations, and treatment of juvenile rheumatoid arthritis (JRA) that have appeared during the past year. One epidemiologic study suggested a decreased incidence recently; however, changes over time in the ethnic and racial characteristics of the patients studied may also have played a role. Findings from an Australian study suggested that some studies may underestimate the true incidence of JRA if visits of physicians are the only basis for the studies. Finally, a Canadian study of incidence showed no seasonal correlations--except for the Prairie region--raising the possibility that the disease varies by region because of environmental factors or variations in ethnic background. Differential diagnostic issues were covered in several reports. One study suggested that elevations in lactate dehydrogenase levels identified children with malignancies who presented with musculoskeletal symptoms. Another study of children with Lyme disease failed to find any patients with asymmetric joint involvement, in contrast to JRA patients. Two studies from Europe reached opposite conclusions regarding whether the incidence of celiac disease was increased in JRA patients. Clinical studies included a French study showing increased production of interleukin-6 and interleukin-1-Ra during fever spikes in children with systemic JRA. An Italian study explored the potential role of interleukin-6 in the anemia of JRA patients. An American study confirmed decreases in markers of bone formation in JRA patients. Two treatment studies addressed the use of intravenous gamma globulin in JRA. Another report described two JRA patients who developed nodules while receiving methotrexate. Finally, a report added confirmation to the successful use of cyclosporine for macrophage activation syndrome in JRA.

Recalcitrant pyoderma gangrenosum-two cases successfully treated with cyclosporin A

The successful use of cyclosporin A (CSA) in organ transplantation is now well established. In recent years its usefulness has extended to the treatment of cutaneous autoimmune disorders, including pyoderma gangrenosum (P.G.). We report two further cases of recalcitrant P.G., both associated with rheumatoid arthritis (R.A.) which responded to low dose CSA.

Successful use of cyclosporine for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis

Successful use of cyclosporine for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis